DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Erbitux (Cetuximab) - Current Clinical Trials

 
 



Erbitux Related Clinical Trials

Phase 1 and 2 Study of PX-866 and Cetuximab [Completed]

An Observational Study of Erbitux� in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment [Terminated]

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) [Completed]

Regorafenib and Cetuximab in Patients With Advanced Malignancy [Recruiting]

Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab [Recruiting]

Pre-op Rectal ChemoRad +/- Cetuximab [Active, not recruiting]

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib [Withdrawn]

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma [Recruiting]

Erlotinib in Combination With Cetuximab [Completed]

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer [Terminated]

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) [Not yet recruiting]

EMMA-1 (Erbitux for Multiple Myeloma) [Terminated]

Reirradiation and Erbitux in the HNSCC [Recruiting]

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer [Not yet recruiting]

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) [Withdrawn]

Sirolimus and Cetuximab in Advanced Malignancies [Completed]

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer [Terminated]

Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer [Completed]

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) [Completed]

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment [Completed]

Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck [Completed]

Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers [Recruiting]

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer [Active, not recruiting]

Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) [Completed]

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer [Completed]

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer [Recruiting]

Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® [Completed]

Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer [Recruiting]

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer [Completed]

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination [Recruiting]

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy [Recruiting]

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck [Terminated]

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer [Completed]

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver [Withdrawn]

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer [Completed]

Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer [Recruiting]

Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer [Completed]

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery [Active, not recruiting]

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer [Recruiting]

Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer [Completed]

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer [Recruiting]

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma [Recruiting]

Cetuximab for Elderly Patients With mCRC [Active, not recruiting]

Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma [Completed]

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer [Terminated]

Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer [Completed]

Mitoxantrone � Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) [Active, not recruiting]

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) [Recruiting]

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma [Recruiting]

Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) [Recruiting]

Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer [Recruiting]

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA [Recruiting]

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors [Recruiting]

Cetuximab in Treating Patients With Advanced Solid Tumors [Completed]

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Thereapy for the Treatment of Unrespectable Recurrent Squamous Cell Carcinoma of the Head and Neck [Recruiting]

Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) [Not yet recruiting]

Preoperative Treatment With Cetuximab and/or IMC-A12 [Active, not recruiting]

Erbitux MEtastatic Colorectal Cancer Strategy Study [Recruiting]

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer [Completed]

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer [Completed]

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer [Completed]

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients [Active, not recruiting]

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer [Completed]

Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy [Completed]

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC [Completed]

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab [Completed]

Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer [Terminated]

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC [Completed]

Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Completed]

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Recruiting]

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer [Completed]

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer [Terminated]

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer [Active, not recruiting]

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC [Terminated]

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects [Completed]

Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma [Withdrawn]

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab [Completed]

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design [Recruiting]

Study of Sorafenib/Cetuximab in Head and Neck Cancer [Completed]

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces [Completed]

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer [Completed]

Lapatinib and Cetuximab in Patients With Solid Tumors [Completed]

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab [Active, not recruiting]

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck [Withdrawn]

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer [Active, not recruiting]

Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients [Completed]

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Completed]

Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer [Active, not recruiting]

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea [Completed]

A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck [Recruiting]

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer [Completed]

Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer [Active, not recruiting]

FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer [Completed]

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer [Recruiting]

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer [Terminated]

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN [Recruiting]

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer [Active, not recruiting]

A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck [Terminated]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015